Breaking the non-responsiveness of C57BL/6 mice to the malarial antigen EB200 - The role of carrier and adjuvant molecules

Scandinavian Journal of Immunology

Volumn 58, Issue 4, 2003, Pages 395-403

  Rahman, Q K ^a,c   Berzins, K ^a   Lopez M C ^b   Fernandez C ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CARRIER PROTEIN; CHOLERA TOXIN; DRUG CARRIER; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN 70; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; PROTEIN EB200; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; HUMORAL IMMUNITY; HYBRIDOMA CELL CULTURE; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TRYPANOSOMA CRUZI;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; IMMUNE SYSTEM; MALARIA, FALCIPARUM; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM;

EID: 0141482052     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01294.x     Document Type: Article

References (34)

1. Mattei D, Scherf A. The Pf332 gene of Plasmodium falciparum codes for a giant protein that is translocated from the parasite to the membrane of infected erythrocytes. Gene 1992;110:71-9.
2. Perraut R, Mercereau-Puijalon O, Mattei D et al. Induction of opsonizing antibodies after injection of recombinant Plasmodium falciparum vaccine candidate antigens in preimmune Saimiri sciureus monkeys. Infect Immun 1995;63:554-62.
3. Ahlborg N, Haddad D, Siddique AB, Roussilhon C, Troye-Blomberg M, Berzins K. Antibody responses to the repetitive Plasmodium falciparum antigen Pf332 in humans naturally primed to the parasite. Clin Exp Immunol 2002;129:318-25.
4. k restricted T-cell epitopes in the highly repetitive Plasmodium falciparum antigen Pf332. Mol Immunol 1997;34:379-89.
5. Herzenberg LA, Tokuhisa T, Herzenberg MA. Carrier priming leads to hapten specific suppression. Nature (London) 1980;285:664-7.
6. Sinigaglia F, Guttinger M, Kilgus J et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988;336:778-80.
7. Kumar A, Arora Rk, Kaur P, Chauhan VS, Sharma P. Universal T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide. J Immunol 1992;23:1499-505.
8. Sharma P, Kumar A, Batni S, Chauhan VS. Co-dominant and reciprocal T-helper cell activity of epitopic sequences and formation of junctional B-cell determinants in synthetic T : B chimeric immunogens. Vaccine 1993;11:1321-6.
9. Ouaissi A, Ouaissi M, Sereno D. Glutathione S-transferases and related proteins from pathogenic human parasites behave as immunomodulator factors. Immunol Lett 2002;81:159-64.
10. Dresser DW. Effectiveness of lipid and lipidophilic substances as adjuvants. Nature 1961;191:1169-71.
11. Hornquist E, Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol 1993;148:2136-43.
12. Kateley JR, Kasaro L, Friedman H. Modulation of in vivo antibody responses by cholera toxin. J Immunol 1975;114:81-4.
13. Bromander A, Holmgren J, Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol 1991;146:2908-14.
14. Lycke N. The mechanism of cholera toxin adjuvanticity. Res Immunol 1997;148:504-20.
15. Elson CO, Ogra PL, Mesteky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, eds. Mucosal adjuvants. In: Mucosal Immunology. San Diego: Academic Press, 1999:817.
16. Rico AI, Angel SO, Alonso C, Requena JM. Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83. Mol Immunol 1999;36:1131-9.
17. Asea A, Kraeft SK, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-42.
18. Ang D, Liberek K, Skowyra D, Zylicz M, Georgopoulos C. Biological role and regulation of the universally conserved heat shock proteins. J Biol Chem 1991;266:24233-6.
19. Gupta RK. Aluminium compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998;32:155-72.
20. Sallberg M, Ruden U, Magnius LO, Norrby E, Wahren B. Rapid 'tea-bag' peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett 1991;30:59-68.
21. Rougon G, Ceard B, Van Rietschoten J, Jordan B, Barber J. Induction with a synthetic peptide of antibodies to HLA class I C-terminal intracytoplasmic region. Mol Immunol 1984;6:461-8.
22. Berzofsky JA. Mechanisms of T cell recognition with application to vaccine design. Mol Immunol 1991;28:217-23.
23. Brett SJ, Cease KB, Berzofsky JA. Influences of antigen processing on the expression of the T-cell repertoire. J Exp Med 1988;168:357-72.
24. Babbit BP, Matsueda G, Haber E, Unanue ER, Allen PM. Antigenic competition at the level of peptide-Ia binding. Proc Natl Acad Sci USA 1986;83:4509-13.
25. Gammon G, Shastri N, Cogswell J et al. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as the determinant site. Immunol Rev 1987;98:53-7.
26. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 1990;11:205-14.
27. Freund J. The effect of paraffin oil and mycobacteria on antibody formation and sensitization. A Review. Am J Clin Pathol 1951;21:645-56.
28. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M. Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 1998;10:609-17.
29. Chen D, Androlewicz MJ. Heat shock protein 70 moderately enhances peptide binding and transport by the transporter associated with antigen processing. Immunol Lett 2001;75:143-8.
30. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem 2001;276:17163-71.
31. Srivastava PK. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2:185-94.
32. Watts TH, Alaverdi N, Wade WF, Linsley PS. Induction of costimulatory molecule B7 in M12 B lymphomas by cAMP or MHC restricted T-cell interaction. J Immunol 1993;150:2192-202.
33. Agren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B-cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997;158:3936-46.
34. Ågren L, Sverremark E, Ekman L et al. The ADP-ribosylating CTA1-DD adjuvant enhances T-cell dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2-and germinal center promoting effects. J Immunol 2000;162:2432-40.